Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD9S | ISIN: HK0000658531 | Ticker-Symbol: S2P
Frankfurt
29.08.25 | 08:03
1,520 Euro
+7,04 % +0,100
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
SIMCERE PHARMACEUTICAL GROUP LTD Chart 1 Jahr
5-Tage-Chart
SIMCERE PHARMACEUTICAL GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,4801,61016:00
1,4901,61029.08.

Aktuelle News zur SIMCERE PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSIMCERE PHARMA (02096): CONNECTED TRANSACTION IN RELATION TO THE ACQUISITIONS OF (1) ASSETS OF SANROAD SHANGHAI AND (2) ENTIRE EQUITY INTEREST IN XIANWEI2
22.08.SIMCERE PHARMA (02096): GRANT OF AWARDS UNDER THE 2021 RSU SCHEME1
21.08.SIMCERE PHARMA (02096): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE-
21.08.SIMCERE PHARMA (02096): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE-
21.08.SIMCERE PHARMA (02096): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 20251
SIMCERE PHARMACEUTICAL Aktie jetzt für 0€ handeln
11.08.SIMCERE PHARMA (02096): DATE OF BOARD MEETING-
10.07.Simcere Pharmaceutical seeks China approval for atopic dermatitis treatment1
09.07.Connect Biopharma Holdings Limited: Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China1
08.07.SIMCERE PHARMA (02096): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF RADEMIKIBART WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION1
03.07.SIMCERE PHARMA (02096): VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF ENZESHU IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2
23.06.Idorsia Pharmaceuticals Ltd: Idorsia's QUVIVIQ expands into China as Simcere receives NDA approval - Idorsia and Simcere update their licensing agreement460Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones...
► Artikel lesen
23.06.SIMCERE PHARMA (02096): DISCLOSEABLE TRANSACTION - AMENDMENT TO THE LICENSE AGREEMENT WITH IDORSIA1
20.06.SIMCERE PHARMA (02096): VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF QUVIVIQ IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION-
19.06.Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma103SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced...
► Artikel lesen
17.06.NextCure and Simcere partner to develop SIM0505 for solid tumours14
16.06.NextCure advances ADC pivot with $745M deal for Simcere's phase 1 drug3
16.06.NextCure partners with Simcere Zaiming on cancer drug development2
16.06.NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6266NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected...
► Artikel lesen
16.06.SIMCERE PHARMA (02096): VOLUNTARY ANNOUNCEMENT - ENTERING INTO LICENSE AGREEMENT WITH NEXTCURE IN RELATION TO ADCS1
13.06.SIMCERE PHARMA (02096): (UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024-
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1